Mångmiljardaffär i jakten på nästa blockbuster inom cancer

Bristol Myers Squibb betalar upp till 11,1 miljarder dollar, motsvarande 106 miljarder kronor, för att köpa in sig i en av de hetaste läkemedelskandidaterna inom immunonkologi.

“You discover one thing – and then 10 new questions arise”

COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

How Volume EM Advances Life Science Research

Free webinar series.

19 medicines in Sweden are under investigation in a major EMA inquiry

19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Am...

Novo Nordisk sues compounding pharmacies in the US

Novo Nordisk is suing compounding pharmacies in Florida, USA, because the company claims to have found impurities in the active ingredient in the obesity drug Wegovy.

Novo Nordisk buys drug candidate in billion dollar deal

The Danish pharmaceutical giant Novo Nordisk have made an agreement with KBP Biosciences to aqcuire the hypertension drug ocedurenone for up to 1.3 billion doll...

New rules for diagnostic products, but who will certify them? “An extreme shortage area”

In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and...

Science to Market - S2M

Kompauto Nordic AB

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American ph...

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Göran Stiernstedt: “We are the world’s worst at continuity”

. “It makes me extremely frustrated,” he says.

The First Multi-Technology System from ZEISS

Microscope and measuring machine in one.

EXCL Gantry Kit Improve Automated Lab Applications

We’re excited to introduce a new product that improves precision and throughput in life science applications. The EXCL multi-axis gantry kit lowers engineering ...

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration o...

Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy

Case study by ZEISS Microscopy.

Nytt läkemedel ska förenkla behandling av blödarsjuka

En ny typ av behandling mot hemofili, som bara behöver ges varannan månad, har godkänts av den amerikanska läkemedelsmyndigheten FDA.

CROs in drug development: "We use our expertise to speed up the process

Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...

No demand for new Covid vaccine – “It will probably be discarded”

So far, just under 6 000 doses of the Covid vaccine from Novavax have been used in Sweden, leaving over 1.4 million doses in stock. “They will probably be disca...

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...